Amendment: SEC Form SC 13G/A filed by Praxis Precision Medicines Inc.

11/14/24 7:53:30 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $PRAX alert in real time by email

SC 13G/A 1 p24-3173sc13ga.htm

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


SCHEDULE 13G/A

Under the Securities Exchange Act of 1934
(Amendment No. 2)*

Praxis Precision Medicines, Inc.
(Name of Issuer)

Common Stock, par value $0.0001 per share
(Title of Class of Securities)

74006W207
(CUSIP Number)

September 30, 2024
(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

¨	Rule 13d-1(b)
ý	Rule 13d-1(c)
¨	Rule 13d-1(d)

(Page 1 of 11 Pages)

______________________________

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 74006W207

13G/A

Page 2 of 11 Pages

1	NAME OF REPORTING PERSON Point72 Asset Management, L.P.
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP		(a) ¨ (b) x
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER 0
	6	SHARED VOTING POWER 1,694,274 shares of Common Stock (including 150,000 shares of Common stock issuable upon exercise of options and 511,030 shares of Common Stock issuable upon exercise of warrants)
	7	SOLE DISPOSITIVE POWER 0
	8	SHARED DISPOSITIVE POWER 1,694,274 shares of Common Stock (including 150,000 shares of Common stock issuable upon exercise of options and 511,030 shares of Common Stock issuable upon exercise of warrants)
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,694,274 shares of Common Stock (including 150,000 shares of Common stock issuable upon exercise of options and 511,030 shares of Common Stock issuable upon exercise of warrants)
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES			¨
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 9.3%
12	TYPE OF REPORTING PERSON PN

CUSIP No. 74006W207

13G/A

Page 3 of 11 Pages

1	NAME OF REPORTING PERSON Point72 Capital Advisors, Inc.
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP		(a) ¨ (b) x
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER 0
	6	SHARED VOTING POWER 1,694,274 shares of Common Stock (including 150,000 shares of Common stock issuable upon exercise of options and 511,030 shares of Common Stock issuable upon exercise of warrants)
	7	SOLE DISPOSITIVE POWER 0
	8	SHARED DISPOSITIVE POWER 1,694,274 shares of Common Stock (including 150,000 shares of Common stock issuable upon exercise of options and 511,030 shares of Common Stock issuable upon exercise of warrants)
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,694,274 shares of Common Stock (including 150,000 shares of Common stock issuable upon exercise of options and 511,030 shares of Common Stock issuable upon exercise of warrants)
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES			¨
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 9.3%
12	TYPE OF REPORTING PERSON CO

CUSIP No. 74006W207

13G/A

Page 4 of 11 Pages

1	NAME OF REPORTING PERSON Point72 Biotech Private Investments, LLC
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP		(a) ¨ (b) x
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER 0
	6	SHARED VOTING POWER 65,933
	7	SOLE DISPOSITIVE POWER 0
	8	SHARED DISPOSITIVE POWER 65,933
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 65,933
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES			¨
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0.4%
12	TYPE OF REPORTING PERSON OO

CUSIP No. 74006W207

13G/A

Page 5 of 11 Pages

1	NAME OF REPORTING PERSON Differentiated Ventures Investments, LLC
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP		(a) ¨ (b) x
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER 0
	6	SHARED VOTING POWER 65,933
	7	SOLE DISPOSITIVE POWER 0
	8	SHARED DISPOSITIVE POWER 65,933
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 65,933
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES			¨
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0.4%
12	TYPE OF REPORTING PERSON OO

CUSIP No. 74006W207

13G/A

Page 6 of 11 Pages

1	NAME OF REPORTING PERSON 72 Investment Holdings, LLC
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP		(a) ¨ (b) x
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER 0
	6	SHARED VOTING POWER 65,933
	7	SOLE DISPOSITIVE POWER 0
	8	SHARED DISPOSITIVE POWER 65,933
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 65,933
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES			¨
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0.4%
12	TYPE OF REPORTING PERSON OO

CUSIP No. 74006W207

13G/A

Page 7 of 11 Pages

1	NAME OF REPORTING PERSON Steven A. Cohen
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP		(a) ¨ (b) x
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION United States
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER 0
	6	SHARED VOTING POWER 1,760,207 shares of Common Stock (including 150,000 shares of Common stock issuable upon exercise of options and 511,030 shares of Common Stock issuable upon exercise of warrants)
	7	SOLE DISPOSITIVE POWER 0
	8	SHARED DISPOSITIVE POWER 1,760,207 (including 150,000 shares of Common stock issuable upon exercise of options and 511,030 shares of Common Stock issuable upon exercise of warrants)
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,760,207 shares of Common Stock (including 150,000 shares of Common stock issuable upon exercise of options and 511,030 shares of Common Stock issuable upon exercise of warrants)
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES			¨
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 9.6%
12	TYPE OF REPORTING PERSON IN

CUSIP No. 74006W207

13G/A

Page 8 of 11 Pages

Item 1(a).	Name of Issuer.
	Praxis Precision Medicines, Inc. (the “Issuer”).

Item 1(b).	Address of Issuer's Principal Executive Offices.
	99 High Street, 30th Floor, Boston, MA 02110.

Item 2(a).

Name of Person Filing.

This statement is filed by: (i) Point72 Asset Management, L.P. (“Point72 Asset Management”) with respect to shares of common stock, par value $0.0001 per share (“Common Stock”), of the Issuer held by (and shares of Common Stock underlying the warrants and options held by) Point72 Associates, LLC, an investment fund it manages (“Point72 Associates”); (ii) Point72 Capital Advisors, Inc. (“Point72 Capital Advisors Inc.”) with respect to shares of Common Stock held by (and shares of Common Stock underlying the warrants and options held by) Point72 Associates; (iii) Point72 Biotech Private Investments, LLC (“Point72 Biotech”) with respect to shares of Common Stock of which it is the holder; (iv) Differentiated Ventures Investments, LLC (“Differentiated Ventures”), the managing member of Point72 Biotech, with respect to the shares of Common Stock held by Point72 Biotech; (v) 72 Investment Holdings, LLC (“72 Investment Holdings”), the sole member of Differentiated Ventures, with respect to the shares of Common Stock held by Point72 Biotech, and (vi) Steven A. Cohen (“Mr. Cohen”) with respect to shares of Common Stock beneficially owned by Point72 Asset Management, Point72 Capital Advisors Inc., Point72 Biotech, Differentiated Ventures, and 72 Investment Holdings.

Item 2(b).	Address of Principal Business Office.
	The address of the principal business office of Point72 Asset Management, Point72 Capital Advisors Inc., Point72 Biotech, Differentiated Ventures, 72 Investment Holdings, and Mr. Cohen is 72 Cummings Point Road, Stamford, CT 06902.

Item 2(c).	Place of Organization.
	Point72 Asset Management is a Delaware limited partnership. Point72 Capital Advisors Inc. is a Delaware corporation. Point72 Biotech, Differentiated Ventures, and 72 Investment Holdings are Delaware limited liability companies. Mr. Cohen is a United States citizen.

Item 2(d).	Title of Class of Securities.
	Common Stock, par value $0.0001 per share.

Item 2(e).	CUSIP Number.
	74006W207

Item 3.	If this Statement is Filed Pursuant to §§ 240.13d-1(b) or 240.13d-2(b), or (c), check whether the Person Filing is a:
	Not applicable.

CUSIP No. 74006W207

13G/A

Page 9 of 11 Pages

Item 4.	Ownership.
	The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person. Such information is as of the close of business on September 30, 2024.

	Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen own directly no shares of Common Stock. Pursuant to an investment management agreement, Point72 Asset Management maintains investment and voting power with respect to securities held by Point72 Associates. Point72 Capital Advisors, Inc. is the general partner of Point72 Asset Management. Mr. Cohen controls each of Point72 Asset Management and Point72 Capital Advisors Inc.

	Differentiated Ventures is the managing member of Point72 Biotech and may be deemed to share beneficial ownership over the shares of Common Stock held by Point72 Biotech. 72 Investment Holdings is the sole member of Differentiated Ventures and may be deemed to share beneficial ownership of the shares of Common Stock of which Differentiated Ventures may be deemed the beneficial owner.

	The filing of this statement should not be construed as an admission that any of the foregoing persons or any reporting person is, for the purposes of Section 13 of the Act, the beneficial owner of the Common Stock reported herein.

	The aggregate percentage of the Common Stock reported to be beneficially owned by each Reporting Person is based on 18,268,099 shares of Common Stock outstanding which is the sum of: (i) 17,757,069 shares of Common Stock outstanding as of August 9, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 13, 2024; and (ii) 511,030 warrant shares exercised as reported herein.

Item 5.	Ownership of Five Percent or Less of a Class.
	If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [ ].

Item 6.	Ownership of More Than Five Percent on Behalf of Another Person.
	Point72 Associates has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, more than 5 percent of the outstanding shares of Common Stock.

Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not applicable.

Item 8.	Identification and Classification of Members of the Group.
	Not applicable.

Item 9.	Notice of Dissolution of Group.
	Not applicable.

CUSIP No. 74006W207

13G/A

Page 10 of 11 Pages

Item 10.

Certification.

By signing below each Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

CUSIP No. 74006W207

13G/A

Page 11 of 11 Pages

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Date: November 14, 2024
	POINT72 ASSET MANAGEMENT, L.P.

	By:	/s/ Jason M. Colombo
	Name:		Jason M. Colombo
	Title:		Authorized Person

	POINT72 CAPITAL ADVISORS, INC.

	By:	/s/ Jason M. Colombo
	Name:	Jason M. Colombo
	Title:	Authorized Person

	POINT72 BIOTECH PRIVATE INVESTMENTS, LLC

	By:	/s/ Vincent Tortorella
	Name:	Vincent Tortorella
	Title:	Authorized Person

	DIFFERENTIATED VENTURES INVESTMENTS, LLC

	By:	/s/ Vincent Tortorella
	Name:	Vincent Tortorella
	Title:	Authorized Person

	72 INVESTMENT HOLDINGS, LLC

	By:	/s/ Jason M. Colombo
	Name:	Jason M. Colombo
	Title:	Authorized Person

	STEVEN A. COHEN
	By:	/s/ Jason M. Colombo
	Name:	Jason M. Colombo
	Title:	Authorized Person

Get the next $PRAX alert in real time by email

Date	Price Target	Rating	Analyst
5/7/2025	$80.00	Buy	Chardan Capital Markets
3/3/2025	$120.00 → $105.00	Buy	H.C. Wainwright
2/11/2025	$111.00	Buy	Deutsche Bank
8/5/2024	$134.00	Outperform	Oppenheimer
6/24/2024	$145.00	Buy	Needham
6/18/2024	$155.00	Buy	Guggenheim
5/1/2024	$117.00	Outperform	Robert W. Baird
9/19/2023	$10.00	Buy	Truist

Amendment: SEC Form SC 13G/A filed by Praxis Precision Medicines Inc.

Chat with this insight

Recent Analyst Ratings for
$PRAX

$PRAX
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Chardan Capital Markets initiated coverage on Praxis Precision Medicines with a new price target

H.C. Wainwright reiterated coverage on Praxis Precision Medicines with a new price target

Deutsche Bank initiated coverage on Praxis Precision Medicines with a new price target

$PRAX
Press Releases

Fastest customizable press release news feed in the world

Praxis Precision Medicines Highlights DEE Clinical Program Updates at Virtual Investor Event

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial Results

$PRAX
Leadership Updates

Live Leadership Updates

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2022 Financial Results

Praxis Precision Medicines Adds Global Business Expertise to Board of Directors with Appointment of Jill DeSimone

Praxis Precision Medicines Announces Management Team Appointments

$PRAX
SEC Filings

Praxis Precision Medicines Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

SEC Form 10-Q filed by Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$PRAX
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Desimone Jill bought $25,375 worth of shares (14,500 units at $1.75) (SEC Form 4)

$PRAX
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

$PRAX
Large Ownership Changes

This live feed shows all institutional transactions in real time.

General Counsel and Secretary Nemiroff Alex covered exercise/tax liability with 51 shares, decreasing direct ownership by 0.24% to 20,832 units (SEC Form 4)

Principal Accounting Officer Mastrocola Lauren covered exercise/tax liability with 40 shares, decreasing direct ownership by 0.38% to 10,442 units (SEC Form 4)

Chief Executive Officer Souza Marcio covered exercise/tax liability with 401 shares, decreasing direct ownership by 0.74% to 53,559 units (SEC Form 4)